Moreover, higher concentrations of APRIL may promote resistance to lenalidomide, bortezomib and other standard-of-care drugs, and also may drive expression of programmed cell death ligand 1 PD-L1, interleukin (IL)-10, and TGFβ on BCMA+ tumor cells creating an immunosuppressive niche that favors tumor cells (266). The gene discussed is TGFB1; the disease is neoplasm.